Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (263)
- Legislation (86)
- COVID-19 (66)
- Compliance and enforcement (56)
- Vaping hub (48)
- Manufacturing (31)
- Import and export (24)
- Labelling and packaging (21)
- Medicinal cannabis hub (20)
- Scheduling (national classification system) (19)
- Safety monitoring and information (15)
- Weight loss products (7)
- Shortages and supply disruptions (4)
- Cosmetics (3)
- Committees and advisory bodies (2)
- Prescription opioids hub (2)
- Sunscreens (2)
- Unique Device Identification (UDI) hub (2)
- Clinical trials (1)
- Fees and payments (1)
- Urogynaecological (transvaginal) surgical mesh hub (1)
Search
720 result(s) found, displaying 551 to 575
-
Media releasesXofluza approved as part of an international work-sharing initiative between the TGA, Health Canada and Swissmedic
-
Media releasesCaruso's Natural Health pays $12,600 fine for false certification in relation to therapeutic good
-
Media releasesJuice Plus Company Australia Pty Ltd has paid penalties of $37,800 for alleged advertising breaches relating to vitamin products
-
Media releasesInSkin Cosmedics Group Pty Ltd has paid penalties of $37,800 in regards to the alleged supply and advertising of the Dermapen 4
-
Media releasesMeasles vaccine testing shows the vaccine meets required standards
-
-
Media releasesPharmacies and others can advertise availability of OTC salbutamol products during the bushfire season
-
Regulatory decision noticesOn 20 November 2019 the TGA issued a direction notice to Cat Media concerning its advertising of Fatblaster Clinical
-
Media releasesMundipharma Pty Ltd has paid penalties of $302,400 in response to 24 infringement notices issued by the TGA
-
-
Regulatory decision noticesA new S41BD(3) instrument has been signed to declare that some nappy rash products are not to be medical devices for the purposes of the Act
-
Regulatory decision noticesThe Permissible Ingredients Determination has been updated.
-
Regulatory decision noticesNew requirements for listed medicines containing Andrographis paniculata
-
Media releasesWe will closely consider the judgment including any further improvements that could enhance the regulatory system in Australia.
-
Regulatory decision noticesThe Permissible Ingredients Determination has been updated.
-
Media releasesAcalabrutinib receives approval through the second international collaborative review initiative between the TGA, FDA and Health Canada
-
Media releasesThe TGA has joined the ICMRA and the WHO in a coordinated global approach to fighting antimicrobial resistance
-
Media releasesConsumer Healthcare Products Australia to handle all medicine advertising pre-approval applications
-
Media releasesThe Complementary Healthcare Council of Australia is no longer accepting advertising pre-approval applications
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Indications) Determination has been updated
-
Media releasesThe Therapeutic Goods Administration is aware that a member of the public has purported to be a Commonwealth public official during a recent incident in Melbourne
-
Media releasesA warning to consumers about undergoing procedures using unapproved medical devices
-
Media releasesChanges are coming in November to the advertising pre-approval arrangements for some complementary medicines advertisements
-
Regulatory decision noticesTherapeutic Goods (Declared Goods) Order 2019 consolidates and replaces several instruments
-
Regulatory decision noticesJapan has recently been added to the list of Foreign Countries and Jurisdictions determined to be comparable overseas regulators